Management Presentations to Focus on Depth of Product Pipeline
CORALVILLE, Iowa, Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief
Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March.
Details of KemPharm's presentations are as follows:
| Event: |
|
BIO CEO & Investor Conference |
| Date: |
|
Tuesday, February 14, 2017 |
| Time: |
|
11:30 a.m. (ET) |
| Location: |
|
The Waldorf Astoria, New York, NY |
| Event: |
|
RBC Capital Markets 2017 Global Healthcare Conference |
| Date: |
|
Wednesday, February 22, 2017 |
| Time: |
|
9:00 a.m. (ET) |
| Location: |
|
The New York Palace Hotel, New York, NY |
| Event: |
|
Cowen & Co. 36th Annual Health Care Conference
2017 |
| Date: |
|
Tuesday, March 7, 2017 |
| Time: |
|
8:00 a.m. (ET) |
| Location: |
|
The Boston Marriott Copley Place, Boston, MA |
| Event: |
|
29th Annual ROTH Conference |
| Date: |
|
Conference Date March 12-15, 2017 |
| Time: |
|
Presentation date/time to be scheduled |
| Location: |
|
The Ritz Carlton, Dana Point, CA |
| Event: |
|
Oppenheimer & Co. 27th Annual Healthcare
Conference |
| Date: |
|
Tuesday, March 21, 2017 |
| Time: |
|
9:45 a.m. (ET) |
| Location: |
|
The Westin New York Grand Central, New York, NY |
All presentation webcasts will available on the Investor Relations section of the KemPharm website at http://investors.kempharm.com/ following delivery at the respective conferences.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of
proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology.
KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of
pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical
development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an
acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For
more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 jrando@tiberend.com jdrumm@tiberend.com Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 dcohen@kempharm.com
